Menu Close

The Importance of Diversity in Cancer Clinical Trials

patient undergoing a cancer clinical trial

Enhancing Patient Representation

In the fight against cancer, diversity isn’t optional – it’s a critical piece of the puzzle towards finding effective treatments for all. While strides have been made in developing innovative therapy methods and discovering potential cures, the underrepresentation of certain groups in clinical trials represents a glaring gap in our stride toward progress.

Although African Americans and Hispanic Americans constitute 13% and 16% of the US population, less than 5% and only 1% of these respective populations participate in clinical trials.

For too long, minority groups, as well as older and rural patients, are often sidelined or overlooked in these life-saving tests.

Here at Lazarex, we believe that everyone of every ethnicity deserves an equal opportunity to fight back against cancer, regardless of their ethnic background or geographical location. In this article, we’ll focus on enhancing patient representation within cancer clinical trials and improving overall healthcare outcomes.

Diversity is crucial in cancer clinical trials to ensure that cancer clinical research findings are applicable to a wide range of patients. Efforts are being made to improve diversity in clinical trials through legislation, recruitment policies, and site selection strategies that consider a wide range of demographics. Additionally, industry sponsors are increasingly prioritizing diversity and collaborating with minority communities to foster trust and inclusion.

Importance of Diversity in Cancer Clinical Trials

Diversity plays a pivotal role in cancer clinical trials, as it ensures that the outcomes and benefits of these trials are applicable to a broader range of patients. Clinical trials provide critical evidence for the development of new treatments, therapies, and medical advancements for every race.

However, if trial participants are not representative of the diverse population affected by cancer, there is a risk of developing treatments that may be less effective or have different side effects for certain racial or ethnic groups.

For instance, White middle-class men make up the majority of trial participants – an estimated 85%, while research shows “African Americans make up 13% of the U.S. population, but just 5% of all clinical trial participants and Hispanics make up 16% of the U.S. population, but only 1% of all clinical trial participants.

This disparity can lead to gaps in understanding how certain cancer treatments may affect different populations and hinder the progress towards equitable healthcare outcomes.

By actively promoting diversity in clinical trials, researchers and scientists can gain insights into how different racial, ethnic, gender, and socioeconomic groups of cancer patients respond to various treatments. This knowledge allows for more personalized and targeted approaches to care, ultimately improving health care outcomes for all patients.

The lack of diverse representation in clinical trials can be likened to a puzzle missing essential pieces. Without all the necessary components, we are unable to paint a comprehensive picture of how different populations respond to treatments and develop the best possible strategies for care.

Impact of Trial Outcomes on Diverse Populations

Clinical trials based on cancer research lay the foundation for advancements in cancer treatment, shaping the path towards better outcomes and improved patient care. However, the lack of diversity in these trials has far-reaching consequences that impact diverse populations.

By excluding underrepresented groups, trial results may not accurately reflect how diverse individuals respond to treatments or the potential side effects they may experience. This can hinder the development of personalized medicine strategies tailored to address the unique needs of diverse populations. Furthermore, it perpetuates health disparities and limits access to cutting-edge therapies for marginalized communities.

For instance, research has shown that certain cancer treatments are less effective or even pose greater risks for specific populations based on genetic variations and other factors. Thus, by excluding these populations from clinical trials, we miss important opportunities to understand treatment efficacy and potential adverse reactions in diverse patients.

To truly advance cancer care for all patients by oncologists, it is crucial to include diverse representation in clinical trials and ensure that trial outcomes pertain to various racial and ethnic backgrounds, genders, ages, and socio-economic statuses. This will lead to more comprehensive data that can guide precision medicine approaches and help deliver equitable access to effective cancer treatments.

Obstacles to Diversity in Cancer Clinical Trials

Despite recognizing the importance of cultural diversity in cancer clinical trials, several obstacles hinder its achievement. Socio-economic factors and trust issues are two significant barriers that prevent adequate representation of diverse populations.

Socio-economic factors play a pivotal role in clinical trial participation as individuals from disadvantaged backgrounds tend to have limited access to healthcare resources and may face financial constraints that inhibit their ability to participate in trials.

Factors such as transportation costs, time off work, and childcare responsibilities can create additional burdens. This disproportionately affects minority communities who often face systemic inequalities that exacerbate these challenges.

Trust issues also contribute to low participation rates among underrepresented populations. Historical instances of abuse and exploitation in medical research, such as the unethical studies conducted on minority populations, have eroded trust in the medical community. This mistrust, coupled with cultural and language barriers, perpetuates skepticism and reluctance to participate in diverse clinical trials.

Health insurance is a big obstacle too.

It’s a dirty little secret in healthcare that insurance often determines what treatment a patient gets, and it frequently has more to do with money (and the cheapest option) than the best medical course of action.

“(Health insurance) helps a lot of people, and insurance companies are a very successful business, but they’re also creating barriers and inequities. Patients are paying for that with their health, and sometimes with their lives,” explains Dana Dornsife, Lazarex Cancer Foundation Founder and Chief Mission & Strategy Officer.

To learn if your insurance is putting your health at risk and what you can do about it, watch this panel discussion at Disrupting the System VI, a Lazarex Cancer Foundation event. 

Despite progress in addressing these obstacles, advocacy efforts must continue to actively engage with communities to foster trust and inclusion. Collaboration between healthcare providers, researchers, and minority communities is essential in order to promote awareness of clinical trial opportunities, educate about the benefits of participation, and address concerns related to the trials’ purpose and potential risks.

Socio-Economic Factors and Trust Issues

diversity in cancer clinical trials is important for finding effective treatments for everyone.

When examining the lack of diversity in cancer clinical trials, socio-economic factors and trust issues play a significant role. Individuals from lower socio-economic backgrounds often face barriers to participating in these trials. Financial constraints, limited access to healthcare facilities, and lack of resources can make it challenging for them to engage in research opportunities. Additionally, historical instances such as the Tuskegee Study have led to understandable mistrust among minority communities, which further hinders their participation.

For instance, minority populations may be skeptical about clinical trials due to past experiences of exploitation or mistreatment within the healthcare system. This mistrust can be deeply ingrained and passed down through generations, creating a barrier that needs to be addressed.

To address these challenges, fostering trust is crucial. Researchers and healthcare providers must actively engage with underrepresented communities to establish open lines of communication and build relationships based on transparency and respect. By addressing socio-economic factors and demonstrating a genuine commitment to understanding and meeting the needs of diverse populations, we can begin to bridge this gap.

The lack of diversity in cancer clinical trials can be attributed to socio-economic factors and trust issues. Lower socio-economic individuals face barriers such as financial constraints, limited access to healthcare facilities, and lack of resources that hinder their participation in research opportunities.

Additionally, historical instances of exploitation and mistreatment, like the Tuskegee Study, have led to understandable mistrust among minority communities.

To address this, it is crucial for researchers and healthcare providers to actively engage with underrepresented communities and establish open lines of communication based on transparency and respect. By addressing these challenges and demonstrating a genuine commitment to understanding the needs of diverse populations, we can work towards bridging the gap in representation in clinical trials.

Advocacy Efforts

Lazarex Cancer Foundation is the only non-profit in the country that facilitates equitable access to FDA cancer clinical trials and helps underserved patients achieve financial neutrality by providing ongoing and significant financial reimbursement for travel costs associated with participating in trial research. LCF also works at the community, state, and federal levels to increase health equity and access to comprehensive cancer care – including prevention, screening, treatment, and survivorship.

Here are five ways the non-profit is driving much-needed change around equity and access to cancer clinical trials. 

  1. Helped almost 12,000 patients over 17+ years and continues to work to meet skyrocketing demand through its Lazarex CARE Program.
  2. Launched its IMPACT Study (Improving Patient Access to Cancer Clinical Trials) at several academic centers, including Penn Medicine’s Abramson Cancer Center and UT Southwestern Medical Center. IMPACT places a full-time patient navigator at the institutions to inform patients about the option of taking part in a travel reimbursement program at the time of cancer clinical trial consideration. Doing so increases the number of patients who expressed a willingness to consider participation in a cancer clinical trial by 600% when the patient navigator position was in effect, and the number of patients fell 94%, from 80 enrollments a year to just 5 when the patient navigator position was eliminated.
  3. Successfully advocated for The Food and Drug Administration to change its official guidance around reimbursement, clarifying that it is not coercion when patients are reimbursed for travel expenses to clinical trial sites, but rather fair practice for creating equal access to cancer clinical trials.
  4. Successfully advocated at the state level for legislation in 7 states to reinforce that guidance at the state level. Georgia was the most recent in 2023. Lazarex is currently working to add Florida, New York, Ohio, and Maryland to the list. 
  5. Created 3 Cancer Wellness HUBs to bring cancer information and resources into underserved communities so people can better access care. The program has grown from one physical location in West Philadelphia to now include pop ups extending across 5 zip codes in Philadelphia, plus pop ups in Los Angeles and the San Francisco East Bay. 

Policy and Legislation for Improved Diversity

Recognizing the urgency and importance of enhancing diversity in oncology clinical trials, policy and legislation efforts are being undertaken. The 2023 omnibus spending bill (Public Law 117-328) has mandated diversity action plans for clinical trials used by the FDA to determine drug safety and effectiveness. This is a significant step towards improving clinical trial diversity as it provides a statutory requirement rather than voluntary measures.

The aim of diversity action plans is to encourage investigators to develop strategies for reaching a broad study population right from the start of the trial process.

Through setting enrollment goals based on affected demographics, collecting demographic information, and implementing strategies to enhance representation among underrepresented groups such as racial minorities, age groups, sexes, and socio-economic backgrounds, these plans seek to address knowledge gaps.

Consider these plans as a roadmap, guiding researchers and sponsors to navigate the challenging terrain of diversity in clinical cancer trials. They provide a framework for inclusion and serve as a strong foundation for achieving meaningful representation.

With this legislation in place, it is vital for clinical trial sponsors to proactively integrate diversity plans into their research processes as standard operating procedures. Institutions should internally address clinical trial diversity through partnerships between clinical operations, ethics, compliance offices, and community organizations. By doing so, we can ensure that diverse populations are given fair and equitable opportunities to participate in trials, leading to improved understanding of how drugs work within different demographics.

Role of Industry Sponsors and Federal Mandate

Industry sponsors play a crucial role in promoting diversity in cancer clinical trials. Many pharmaceutical and biotech companies recognize the importance of inclusivity and have started taking steps to address the issue. These sponsors can actively support initiatives that aim to increase representation by partnering with community organizations, supporting outreach programs, and providing funding for diverse populations to participate in trials. Furthermore, federal mandates can also contribute significantly to addressing the lack of diversity by requiring sponsors to develop and submit diversity action plans. These plans outline strategies to achieve demographic equity in clinical trial participation, fostering greater inclusivity and ensuring that the resulting therapeutics are effective for all demographics.

Professional Roles and Community Engagement

To truly enhance patient representation in cancer clinical trials, it is essential for healthcare professionals to take an active role. Oncology practitioners can play a critical part in increasing diversity by engaging in community outreach initiatives. This involves building connections with underserved communities, educating them about the importance of clinical trials, addressing their concerns and misconceptions, and making sure men and women have access to relevant information. By fostering trust and cultivating relationships with potential participants, healthcare professionals can help bridge the gap between research institutions and diverse patient populations.

Moreover, community engagement goes beyond healthcare professionals alone. Various stakeholders, such as patient advocacy groups, community leaders, and grassroots organizations, need to collaborate with healthcare providers to encourage participation from underrepresented groups.They can host informational sessions or workshops, raise awareness about ongoing trials through local media channels or social platforms, and dispel myths surrounding clinical research.

By actively involving themselves in the community and collaborating with different stakeholders, healthcare professionals can foster a culture of inclusion that encourages individuals from diverse backgrounds to participate in cancer clinical trials.

The Role of Oncology Practitioners and Community Outreach

Oncology practitioners, including physicians, nurses, and advanced practitioners, play a vital role in addressing the lack of diversity in cancer clinical trials. They are at the forefront of patient care and have the knowledge and expertise to identify potentially eligible patients for clinical trials. By actively engaging with patients, they can provide information about available trial opportunities and discuss the potential benefits and risks involved.

Through their close relationships with patients, oncology practitioners can build trust and foster a sense of inclusion. This is particularly important when working with minority communities that may have historical mistrust or limited access to healthcare resources. Effective communication ensures that patients feel empowered to make informed decisions about participating in clinical trials.

For instance, imagine a nurse practitioner working with an African American patient diagnosed with cancer. By understanding the patient’s background, concerns, and misconceptions regarding clinical trials, the practitioner can address those fears directly. They can explain the importance of diverse representation in research studies and how participation can help advance medical knowledge for everyone. By tailoring their approach to each individual patient’s needs, they can break down barriers and encourage broader participation.

Community outreach also plays a crucial role in increasing diversity in cancer clinical trials. Engaging with community organizations, advocacy groups, and faith-based organizations allows oncology practitioners to establish meaningful connections within minority communities. This outreach provides an opportunity to educate communities about clinical trial options and dispel myths or misconceptions surrounding them.

When conducting community outreach, it’s important for oncology practitioners to listen actively to community members’ concerns and address their specific cultural or logistical barriers to participation. Collaborating with trusted community leaders can enhance credibility and help bridge any gaps between healthcare providers and community members.

By actively involving minority communities in discussions about clinical trials, oncology practitioners can ensure that trial design takes into account their unique perspectives and needs. This inclusive approach allows for more representative research outcomes and better informs treatment decisions for diverse patient populations.

To learn more about Lazarex, visit